Chest
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To analyze the characteristics of patients admitted for acute pulmonary thromboembolism (PE) and identify whether there are differences in presentation, severity and outcome at discharge of elderly patients (> 75 years) comparing to the younger patients. ⋯ The following authors have nothing to disclose: Pedro Pires Goncalves, Jacinto Hernández Borge, María del Carmen García García, Hernando Chávez Roldán, José Antonio Gutierrez Lara, María José Antona Rodríguez, Amparo Sanz Cabrera, Francisca Lourdes Márquez Pérez, Pilar Cordero Montero, Ignacio Rodríguez BlancoNo Product/Research Disclosure Information.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of patients. Several studies have shown that acute exacerbations (AEs) decrease health-related quality of life, pulmonary function and survival of COPD patients. The objective of the present study was to examine the effects of a physical therapy program on quality of life in COPD patients hospitalized due to an acute exacerbation. ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Angela Ruíz-SáezNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We retrospectively reviewed the complications occurred in the immediate postoperatory (IPO) of lung transplantation (LTx). ⋯ Jordi Rello: Grant monies (from sources other than industry): Study financed partly with Spanish Government Grant FIS PI11/01122 The following authors have nothing to disclose: Jordi Riera, Berta Caralt, Salvador Augustin, Joan Ramon Masclans, Merce Canela, Antonio RomanNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: A 35-year-old African patient goes to pneumologist because of abnormal chest X-ray (during tuberculosis screening at work). ⋯ The following authors have nothing to disclose: Olivier Gilbert, Alain Van Meerhaeghe, Myriam Remmelink, Benjamin Bondue, Matteo Cappello, Paul Devuyst, Philippe PierardNo Product/Research Disclosure Information.